Novartis gains U.S. approval for dairy cattle vaccine

 Resize text         Printer-friendly version of this article Printer-friendly version of this article
Swiss drugs group Novartis said Tuesday it’s recently acquired U.S. vaccine firm ImmTech Biologics has won a
conditional license in the United States to use Treponema Bacterin, a vaccine designed to prevent digital dermatitis — hairy heel warts — in dairy cattle.

“Digital dermatitis is a costly disease for dairy producers and Treponema Bacterin is the only immunological solution available,” said Mark Hodgson, President of Novartis Animal Vaccines Inc., in a statement.
“It allows dairy producers to reduce environmental, worker safety and milk-quality issues associated with chemical and antibiotic management of heel warts,” he added.


Comments (0) Leave a comment 

e-Mail (required)


characters left

Farmall® 100A Series

From field to feedlot, you need a tractor that can multi-task as well as you do. Case IH Farmall™ 100A ... Read More

View all Products in this segment

View All Buyers Guides

Feedback Form
Leads to Insight